OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study
Christelle de la Fouchardière, David Malka, Claire Cropet, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 9, pp. 1055-1066
Closed Access | Times Cited: 11
Christelle de la Fouchardière, David Malka, Claire Cropet, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 9, pp. 1055-1066
Closed Access | Times Cited: 11
Showing 11 citing articles:
New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy
Sofia Dallavalle, Gabriele Campagnoli, Paola Pastena, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1070-1070
Open Access | Times Cited: 6
Sofia Dallavalle, Gabriele Campagnoli, Paola Pastena, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1070-1070
Open Access | Times Cited: 6
Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024
Angelika Kestler, Thomas Seufferlein
Gastroenterologie up2date (2025) Vol. 21, Iss. 01, pp. 25-41
Closed Access
Angelika Kestler, Thomas Seufferlein
Gastroenterologie up2date (2025) Vol. 21, Iss. 01, pp. 25-41
Closed Access
Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma
Adrien Grancher, Leila Tagemouati, André Gillibert, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102583-102583
Open Access
Adrien Grancher, Leila Tagemouati, André Gillibert, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102583-102583
Open Access
Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024
Angelika Kestler, Thomas Seufferlein
TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 03, pp. 176-190
Closed Access
Angelika Kestler, Thomas Seufferlein
TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 03, pp. 176-190
Closed Access
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Pancreatic cancer
Thomas F. Stoop, Ammar A. Javed, Atsushi Oba, et al.
The Lancet (2025) Vol. 405, Iss. 10485, pp. 1182-1202
Closed Access
Thomas F. Stoop, Ammar A. Javed, Atsushi Oba, et al.
The Lancet (2025) Vol. 405, Iss. 10485, pp. 1182-1202
Closed Access
ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer
Thierry Conroy, Michel Ducreux
ESMO Open (2025), pp. 104528-104528
Open Access
Thierry Conroy, Michel Ducreux
ESMO Open (2025), pp. 104528-104528
Open Access
Cancer chemoprevention: signaling pathways and strategic approaches
Junling Ren, Guangli Yan, Le Yang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Junling Ren, Guangli Yan, Le Yang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Yung‐Yeh Su, Nai‐Jung Chiang, Tai‐Jan Chiu, et al.
Biomedical Journal (2023) Vol. 47, Iss. 3, pp. 100696-100696
Open Access | Times Cited: 5
Yung‐Yeh Su, Nai‐Jung Chiang, Tai‐Jan Chiu, et al.
Biomedical Journal (2023) Vol. 47, Iss. 3, pp. 100696-100696
Open Access | Times Cited: 5
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 7
Open Access | Times Cited: 1
Dominik Paul Modest, Volker Heinemann, Philipp Schütt, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 7
Open Access | Times Cited: 1
